Guizhou Sanli Pharmaceutical Co.,Ltd (SHA:603439)
11.51
-0.41 (-3.44%)
Sep 10, 2026, 11:29 AM CST
SHA:603439 Revenue
Guizhou Sanli Pharmaceutical Co.,Ltd had revenue of 177.59M CNY in the quarter ending June 30, 2026, a decrease of -39.44%. This brings the company's revenue in the last twelve months to 1.56B, down -18.99% year-over-year. In the year 2025, Guizhou Sanli Pharmaceutical Co.,Ltd had annual revenue of 1.70B, down -20.59%.
Revenue (ttm)
1.56B
Revenue Growth
-18.99%
P/S Ratio
3.09
Revenue / Employee
826.88K
Employees
1,887
Market Cap
4.82B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.70B | -441.54M | -20.59% |
| Dec 31, 2024 | 2.14B | 509.41M | 31.16% |
| Dec 31, 2023 | 1.63B | 433.66M | 36.10% |
| Dec 31, 2022 | 1.20B | 262.35M | 27.94% |
| Dec 31, 2021 | 938.97M | 308.74M | 48.99% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Luoxin Pharmaceuticals Group Stock | 2.34B |
| Hunan Fangsheng Pharmaceutical | 1.87B |
| Henan Taloph Pharmaceutical Stock Co.,Ltd | 1.73B |
| Bide Pharmatech | 1.38B |
| Beijing Beilu Pharmaceutical | 1.29B |
| Hunan Hansen Pharmaceutical | 1.01B |
| Jiangsu Jibeier Pharmaceutical | 1.00B |
| ChengDu ShengNuo Biotec | 911.15M |